Agents, such as EGFR tyrosine kinase inhibitors (TKIs) and ALK inhibitors, have changed the treatment paradigm for patients with actionable mutations, providing a personalized approach to systemic therapy for lung cancer bone metastases [44]. This evidence concerns the gene EGFR and lung carcinoma.